Skip to content

    HEALTHX

    HEALTHX
    Healthcare·19 Jun 2026
    Management Summary

    Health X Platform Limited reported a strong Q4 and FY26, marked by significant revenue and gross profit growth, and a substantial reduction in EBITDA and PAT losses. The company successfully transitioned to the HealthX identity, launched the JITO initiative for affordable healthcare, and continued to expand its B2B platform, Retailer Shakti. While operational metrics improved, Q4 PAT was impacted by non-operating factors. The company remains focused on technology-driven growth, capital efficiency, and strategic expansion of its warehousing capacity, targeting ₹6,000 crores revenue by FY2030.

    Highlights

    5

    • Revenue from operations increased to ₹356 crores in Q4 FY26, a 22% YoY growth, driven by both B2B and B2C verticals.

    • Gross profit for Q4 FY26 increased by 45% YoY to ₹26.5 crores, with gross margins improving to 7.3% from 5.9% last year.

    • EBITDA losses significantly reduced to ₹20 crores in Q4 FY26 from ₹29 crores in Q4 FY25, representing an improvement of nearly 29%.

    • Full-year FY26 PAT loss reduced significantly to ₹1.4 crores from ₹133 crores in FY25, reflecting a sharp turnaround in profitability.

    • Launched JITO (All Certified Genetic Medicine) category, aiming to make healthcare significantly more affordable by offering medicines at prices up to 60% lower than leading branded alternatives.

    Concerns

    2

    • PAT for Q4 FY26 was a loss of ₹12.9 crores, compared to a profit of ₹17.6 crores in Q4 FY25, primarily due to lower other income and exceptional items.

    • Market readiness for the AI consulting product is not yet high, with management indicating it will take at least six more months before a cautious rollout.

    Key financials

    Metrics

    14

    Periods

    2

    Headline

    8
    • Revenue from Operations (FY)
      ₹1,283 Cr
      YoY+18%
    • Gross Profit (FY)
      ₹96.5 Cr
      YoY+36.5%
    • Gross Margin (FY)
      7.5%
    • EBITDA Loss (FY)
      ₹65 Cr
    • EBITDA Margin (FY)
      -5%

    Q4

    6
    • Revenue from Operations
      ₹356 Cr
      YoY+22%QoQ+4%
    • Gross Profit
      ₹26.5 Cr
      YoY+45%
    • Gross Margin
      7.3%
    • EBITDA Loss
      ₹20 Cr
    • EBITDA Margin
      -5.5%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹234 crores

    ₹134 crores bank loans, ₹100 crores from treasury

    Debt

    Debt disclosed

    Liquidity

    Cash ₹30 crores

    This cash balance is separate from the company's treasury. The company also holds a treasury of ₹400 crores in the operating company and ₹100 crores in Microsec Resources.

    Guidance & targets

    17
    CategoryTargetPriority
    Revenue
    Total Revenue
    ₹6,000 crores
    		High
    Profitability
    EBITDA Margin
    5%
    		High
    Profitability
    PAT/Cash
    4% of revenue
    		High
    Profitability
    Return on Equity (ROE)
    40%
    		High
    Profitability
    Profit (FY29)
    3% of revenue (approx. ₹120 crores)
    		High
    Profitability
    Retailer Shakti EBITDA margin
    1%
    		High
    Profitability
    JITO margins
    30-40%+
    		High
    Capital Deployed
    Capital Deployed (FY29)
    ₹300-400 crores
    		High
    Product Mix
    Non-medicine revenue (Retailer Shakti)
    10% of sales
    		High
    Market Share
    West Bengal market share
    5-7%
    		High
    Market Share
    Northern operations market share
    5-7%
    		High
    Growth
    Northeast growth
    >50%
    		High
    Growth
    Northern India growth
    25-30%
    		High
    Capacity
    Additional warehousing space
    1 lakh sq ft
    		High
    Capacity
    Total warehousing capacity
    >8 lakh sq ft
    		High
    Treasury
    Treasury yield
    10-12% per annum
    		High
    Treasury
    NSE IPO annualized returns
    15%
    		High

    Non-medicine revenue share in Retailer Shakti

    within a year (check next quarter for progress)
    Current~2%
    TargetProgress towards 10% of sales

    Why it matters

    Indicates diversification and higher-margin product mix for the B2B platform, crucial for overall profitability improvement.

    Non-medicine right now is very low, it's around 2% only and we plan to make it by within a year to the extent of 10% of our sales.

    How to verify

    key_financials.segment_breakdown[name='Retailer Shakti'].metrics[label='Non-medicine Revenue Share']

    Risks & concerns

    3
    RiskSeverity

    Market readiness for AI consulting product

    Consumers are not yet habituated to apply AI, requiring more time and capital for scale-up, with a cautious rollout planned in 6 months. — Management acknowledged

    medium

    Capital intensity of hospital business

    The hospital business is credit-driven and not very profitable, which the company avoids due to its highly capital-intensive nature. — Management acknowledged

    medium

    Quarter-to-quarter business variance

    The company's startup nature means performance is not linear, with potential for quarterly fluctuations, though overall growth is expected. — Management acknowledged

    low

    Q&A highlights

    8

    “So, the JITO we have launched in both B2B and B2C platform. So there is no negative surprises. Rather, there is positive surprises. And sales are going well. This is the first quarter only. So before the meaningful figures come in, we can discuss for the next quarter. So, this quarter is the launching year, so in a few lakhs sales around, say, 30 lakhs per month we are doing. So it will take time to build up, but yes, the start is very good.”

    Provides initial qualitative and quantitative feedback on the newly launched strategic JITO initiative.

    asked by Praneeth

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Transition and Ecosystem Expansion

    Health X Platform Limited successfully transitioned to its new identity, reflecting its evolution into a broader healthcare ecosystem encompassing pharmacy distribution, digital healthcare, technology, diagnostics, and preventive care. The company's strategy is built on four enduring principles: innovation, value delivery, impact-driven empathy, and trust, aiming to make healthcare affordable, accessible, and technology-driven. This strategic shift is expected to drive long-term growth and market penetration across India.

    02

    Strong Financial Performance and Margin Improvement

    For Q4 FY26, revenue from operations grew 22% YoY to ₹356 crores, with gross profit increasing 45% YoY to ₹26.5 crores, and gross margins improving to 7.3% from 5.9% last year. Full-year FY26 saw revenue of ₹1283 crores (18% YoY) and gross profit of ₹96.5 crores (36.5% YoY). EBITDA losses significantly reduced from ₹79 crores in FY25 to ₹65 crores in FY26, with EBITDA margin improving to negative 5% from negative 7.3%.

    03

    JITO Initiative and Product Diversification

    The company launched JITO (All Certified Genetic Medicine) to offer high-quality healthcare at prices up to 60% lower than branded alternatives, with initial sales of ₹30 lakhs per month. Beyond medicines, HealthX is expanding into surgical devices, nutraceuticals, and plans for personal and beauty care by the next quarter. This diversification aims for non-medicine revenue to reach 10% of Retailer Shakti's sales within a year, up from the current 2%.

    04

    Capital Efficiency and Future Growth Targets

    HealthX maintains high capital efficiency with a working capital cycle of only 18 days and total capital employed of ₹74 crores. The company targets ₹6,000 crores in revenue by FY2030, with 5% EBITDA margin and 4% PAT/cash, and an ambitious 40% ROE by FY29/FY30. This growth will be supported by an additional ₹234 crores in capex for new warehousing capacity, funded by ₹134 crores in bank loans and ₹100 crores from treasury.

    05

    Demerger of Microsec Resources

    The company is demerging Microsec Resources Ltd., which will be listed separately, with existing shareholders receiving one equity share of Microsec for every three shares held in HealthX. HealthX Platform Limited will retain ₹400 crores of treasury, while Microsec will receive ₹140 crores in assets (₹100 crores financial assets, ₹40 crores real estate). This demerger aims to unlock value, provide tax benefits, and allow HealthX to focus entirely on its core healthcare business, with the treasury in the operating company benefiting from tax efficiency on income.

    06

    Technology and Infrastructure Expansion

    Technology remains central to HealthX's strategy, with centralized, technology-enabled fulfillment infrastructure spanning over 2 lakh square feet. The company plans to add 1 lakh square feet of warehousing space by March 31, FY27, bringing total capacity to over 8 lakh square feet. HealthX is also cautiously preparing for the rollout of AI-driven consulting tools, which are expected to be launched in about six months, emphasizing capital conservatism in deployment.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.